Trial reportCancer science2020
Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.
Trial report in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors.Nature communications · 2022Trial
- Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.Cancer science · 2020Trial
- Article
- Efficacy and safety of systemic treatment for progressive and refractory desmoid tumor: a systematic review and Bayesian network meta-analysis.Discover oncology · 2024Article
- Article
- Current Treatment Concepts for Extra-Abdominal Desmoid-Type Fibromatosis: A Narrative Review.Cancers · 2024Review
- Article
- Clinical results of active surveillance for extra-abdominal desmoid-type fibromatosis.Cancer medicine · 2023Article
- Efficacy of auranofin as an inhibitor of desmoid progression.Scientific reports · 2022Article
- Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.Frontiers in immunology · 2022Article
- Less-invasive fascia-preserving surgery for abdominal wall desmoid.Scientific reports · 2021Article
- Correction.Cancer science · 2021Article
Corrections and comments
- Erratum issuedCorrection.2021
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Low-dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid-type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution. Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.